Cargando…

Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1

The Golgi apparatus is increasingly recognized as a major hub for cellular signaling and is involved in numerous pathologies, including neurodegenerative diseases and cancer. The study of Golgi stress-induced signaling pathways relies on the selectivity of the available tool compounds of which curre...

Descripción completa

Detalles Bibliográficos
Autores principales: Gendarme, Mathieu, Baumann, Jan, Ignashkova, Tatiana I., Lindemann, Ralph K., Reiling, Jan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Cell Biology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739293/
https://www.ncbi.nlm.nih.gov/pubmed/29074567
http://dx.doi.org/10.1091/mbc.E17-03-0176
_version_ 1783287843467034624
author Gendarme, Mathieu
Baumann, Jan
Ignashkova, Tatiana I.
Lindemann, Ralph K.
Reiling, Jan H.
author_facet Gendarme, Mathieu
Baumann, Jan
Ignashkova, Tatiana I.
Lindemann, Ralph K.
Reiling, Jan H.
author_sort Gendarme, Mathieu
collection PubMed
description The Golgi apparatus is increasingly recognized as a major hub for cellular signaling and is involved in numerous pathologies, including neurodegenerative diseases and cancer. The study of Golgi stress-induced signaling pathways relies on the selectivity of the available tool compounds of which currently only a few are known. To discover novel Golgi-fragmenting agents, transcriptomic profiles of cells treated with brefeldin A, golgicide A, or monensin were generated and compared with a database of gene expression profiles from cells treated with other bioactive small molecules. In parallel, a phenotypic screen was performed for compounds that alter normal Golgi structure. Histone deacetylase (HDAC) inhibitors and DNA-damaging agents were identified as novel Golgi disruptors. Further analysis identified HDAC1/HDAC9 as well as BRD8 and DNA-PK as important regulators of Golgi breakdown mediated by HDAC inhibition. We provide evidence that combinatorial HDACi/(+)-JQ1 treatment spurs synergistic Golgi dispersal in several cancer cell lines, pinpointing a possible link between drug-induced toxicity and Golgi morphology alterations.
format Online
Article
Text
id pubmed-5739293
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The American Society for Cell Biology
record_format MEDLINE/PubMed
spelling pubmed-57392932018-03-02 Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1 Gendarme, Mathieu Baumann, Jan Ignashkova, Tatiana I. Lindemann, Ralph K. Reiling, Jan H. Mol Biol Cell Articles The Golgi apparatus is increasingly recognized as a major hub for cellular signaling and is involved in numerous pathologies, including neurodegenerative diseases and cancer. The study of Golgi stress-induced signaling pathways relies on the selectivity of the available tool compounds of which currently only a few are known. To discover novel Golgi-fragmenting agents, transcriptomic profiles of cells treated with brefeldin A, golgicide A, or monensin were generated and compared with a database of gene expression profiles from cells treated with other bioactive small molecules. In parallel, a phenotypic screen was performed for compounds that alter normal Golgi structure. Histone deacetylase (HDAC) inhibitors and DNA-damaging agents were identified as novel Golgi disruptors. Further analysis identified HDAC1/HDAC9 as well as BRD8 and DNA-PK as important regulators of Golgi breakdown mediated by HDAC inhibition. We provide evidence that combinatorial HDACi/(+)-JQ1 treatment spurs synergistic Golgi dispersal in several cancer cell lines, pinpointing a possible link between drug-induced toxicity and Golgi morphology alterations. The American Society for Cell Biology 2017-12-15 /pmc/articles/PMC5739293/ /pubmed/29074567 http://dx.doi.org/10.1091/mbc.E17-03-0176 Text en © 2017 Gendarme et al. This article is distributed by The American Society for Cell Biology under license from the author(s). Two months after publication it is available to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0). “ASCB®,” “The American Society for Cell Biology®,” and “Molecular Biology of the Cell®” are registered trademarks of The American Society for Cell Biology.
spellingShingle Articles
Gendarme, Mathieu
Baumann, Jan
Ignashkova, Tatiana I.
Lindemann, Ralph K.
Reiling, Jan H.
Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1
title Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1
title_full Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1
title_fullStr Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1
title_full_unstemmed Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1
title_short Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1
title_sort image-based drug screen identifies hdac inhibitors as novel golgi disruptors synergizing with jq1
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739293/
https://www.ncbi.nlm.nih.gov/pubmed/29074567
http://dx.doi.org/10.1091/mbc.E17-03-0176
work_keys_str_mv AT gendarmemathieu imagebaseddrugscreenidentifieshdacinhibitorsasnovelgolgidisruptorssynergizingwithjq1
AT baumannjan imagebaseddrugscreenidentifieshdacinhibitorsasnovelgolgidisruptorssynergizingwithjq1
AT ignashkovatatianai imagebaseddrugscreenidentifieshdacinhibitorsasnovelgolgidisruptorssynergizingwithjq1
AT lindemannralphk imagebaseddrugscreenidentifieshdacinhibitorsasnovelgolgidisruptorssynergizingwithjq1
AT reilingjanh imagebaseddrugscreenidentifieshdacinhibitorsasnovelgolgidisruptorssynergizingwithjq1